Wholesale-Drugs, Proprietaries & Druggists' Sundries

The Wholesale-Drugs, Proprietaries & Druggists' Sundries industry, classified under SIC 5122, sits at the center of the pharmaceutical supply chain, purchasing branded and generic prescription drugs, over-the-counter medicines, vitamins, personal care items, and related medical sundries in bulk and distributing them to retail pharmacies, hospital systems, clinics, long-term care facilities, mail-order and online pharmacies, and mass merchandisers. Distributors face tight margins, intense pricing pressure, and significant regulatory oversight, including FDA and DEA controls, drug pedigree and track-and-trace requirements, and complex reimbursement dynamics tied to public and private payors. Key risks include supply chain disruptions, drug shortages, counterfeit products, cybersecurity threats to ordering platforms, and ongoing consolidation among manufacturers and pharmacy chains. In 2024–2025, growth is driven by specialty and biologic therapies, GLP-1 weight-loss and diabetes drugs, investments in cold-chain logistics, data-driven inventory management, and ESG-focused sourcing practices. For investors and professionals tracking this sector, you can view live SEC filings for SIC 5122 companies on EarningsFeed.

Source: Earnings Feed research · last fetched 11/23/2025